New hope for stubborn lymphoma: drug duo aims to wipe out tumors
NCT ID NCT07480850
First seen Mar 21, 2026 · Last updated May 23, 2026 · Updated 13 times
Summary
This study tests a combination of the drug glofitamab with chemotherapy (GemOx) in 40 adults with a type of lymphoma that did not respond to initial treatment. The main goal is to see how many patients have their tumors completely disappear for at least 4 weeks. Participants must be 18 or older and have PET-positive scans after first-line therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, beijing,
Beijing, China
Conditions
Explore the condition pages connected to this study.